We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Kazia is developing a drug called GDC-0084 for the treatment of Glioblastoma (GBM) and other cancers, which was licensed from US pharmaceutical group, Genentech and is currently in phase II human trials
'Tis the season for good deeds, and Boehringer Ingelheim employees are doing their part. BI is once again partnering with the Bonnie J. Addario Lung Cancer Foundation (ALCF) to bring holiday cheer directly to lung cancer patients.